Verve Therapeutics Inc (NASDAQ: VERV) Seen Running Too Hot, Let’s Look At This More Closely

Currently, there are 81.97M common shares owned by the public and among those 54.79M shares have been available to trade.

The company’s stock has a 5-day price change of -36.78% and -40.32% over the past three months. VERV shares are trading -40.32% year to date (YTD), with the 12-month market performance down to -41.82% lower. It has a 12-month low price of $8.22 and touched a high of $21.42 over the same period. VERV has an average intraday trading volume of 1.08 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -39.96%, -37.27%, and -41.48% respectively.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Institutional ownership of Verve Therapeutics Inc (NASDAQ: VERV) shares accounts for 70.24% of the company’s 81.97M shares outstanding.

It has a market capitalization of $653.54M and a beta (3y monthly) value of 1.70. The earnings-per-share (ttm) stands at -$3.13. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.37% over the week and 7.13% over the month.

Analysts forecast that Verve Therapeutics Inc (VERV) will achieve an EPS of -$0.73 for the current quarter, -$0.74 for the next quarter and -$3.22 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.83 while analysts give the company a high EPS estimate of -$0.61. Comparatively, EPS for the current quarter was -$0.84 a year ago. Earnings per share for the fiscal year are expected to increase by 3.77%, and -8.14% over the next financial year.

Looking at the support for the VERV, a number of firms have released research notes about the stock. Canaccord Genuity stated their Buy rating for the stock in a research note on April 13, 2023, with the firm’s price target at $29. Cantor Fitzgerald coverage for the Verve Therapeutics Inc (VERV) stock in a research note released on February 01, 2023 offered a Neutral rating with a price target of $21. Goldman was of a view on December 15, 2022 that the stock is Sell, while Credit Suisse gave the stock Neutral rating on October 06, 2022, issuing a price target of $48. Stifel on their part issued Buy rating on August 25, 2022.

Most Popular

Related Posts